Traders sold shares of Celgene Corp. (NASDAQ:CELG) on strength during trading on Monday. $63.03 million flowed into the stock on the tick-up and $95.35 million flowed out of the stock on the tick-down, for a money net flow of $32.32 million out of the stock. Of all equities tracked, Celgene Corp. had the 0th highest net out-flow for the day. Celgene Corp. traded up $0.41 for the day and closed at $107.93

CELG has been the topic of a number of recent research reports. Robert W. Baird reissued a “buy” rating and set a $162.00 price target on shares of Celgene Corp. in a research note on Tuesday, April 26th. Bank of America Corp. reissued a “buy” rating and set a $125.00 price target on shares of Celgene Corp. in a research note on Monday, April 25th. Vetr lowered Celgene Corp. from a “strong-buy” rating to a “buy” rating and set a $120.74 price target on the stock. in a research note on Thursday, June 2nd. SunTrust Banks Inc. reissued a “buy” rating and set a $147.00 price target (up from $145.00) on shares of Celgene Corp. in a research note on Thursday, April 28th. Finally, Raymond James Financial Inc. reissued a “buy” rating on shares of Celgene Corp. in a research note on Thursday, April 28th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and twenty-one have issued a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $137.29.

The stock has a market cap of $83.60 billion and a PE ratio of 52.50. The company’s 50-day moving average price is $102.13 and its 200 day moving average price is $102.90.

Celgene Corp. (NASDAQ:CELG) last posted its earnings results on Thursday, April 28th. The biopharmaceutical company reported $1.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.29 by $0.03. The firm had revenue of $2.51 billion for the quarter, compared to analysts’ expectations of $2.59 billion. The company’s revenue was up 20.7% compared to the same quarter last year. During the same period in the previous year, the company earned $1.07 earnings per share. Equities analysts forecast that Celgene Corp. will post $5.70 earnings per share for the current fiscal year.

In other news, insider Robert J. Hugin sold 75,000 shares of the stock in a transaction dated Monday, June 20th. The shares were sold at an average price of $100.16, for a total transaction of $7,512,000.00. Following the sale, the insider now directly owns 1,122,201 shares of the company’s stock, valued at approximately $112,399,652.16. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Other hedge funds and institutional investors recently modified their holdings of the company. Synovus Financial Corp raised its position in shares of Celgene Corp. by 16.6% in the fourth quarter. Synovus Financial Corp now owns 8,571 shares of the biopharmaceutical company’s stock worth $1,027,000 after buying an additional 1,222 shares in the last quarter. Genesee Valley Trust Co. raised its position in shares of Celgene Corp. by 4.2% in the fourth quarter. Genesee Valley Trust Co. now owns 8,820 shares of the biopharmaceutical company’s stock worth $1,056,000 after buying an additional 359 shares in the last quarter. Investment Management of Virginia LLC raised its position in shares of Celgene Corp. by 63.0% in the fourth quarter. Investment Management of Virginia LLC now owns 9,043 shares of the biopharmaceutical company’s stock worth $1,083,000 after buying an additional 3,495 shares in the last quarter. NBT Bank N A NY raised its position in shares of Celgene Corp. by 0.3% in the fourth quarter. NBT Bank N A NY now owns 9,248 shares of the biopharmaceutical company’s stock worth $1,107,000 after buying an additional 30 shares in the last quarter. Finally, Johnson Financial Group Inc. raised its position in shares of Celgene Corp. by 2.9% in the fourth quarter. Johnson Financial Group Inc. now owns 9,557 shares of the biopharmaceutical company’s stock worth $1,145,000 after buying an additional 266 shares in the last quarter.

Celgene Corporation (Celgene) is a biopharmaceutical company. The Company together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.